Questions to Ask Your Provider Before Starting GLP-1
The essential questions every patient should ask their healthcare provider before beginning semaglutide or tirzepatide treatment. Covers medication selection, side effects, monitoring, cost, and long-term planning.
More on Provider & Access
About the Medication
Which GLP-1 medication do you recommend for me and why?
Your provider should explain their reasoning for choosing semaglutide vs tirzepatide (or another option) based on your specific health profile, treatment goals, insurance coverage, and comorbidities. There is no one-size-fits-all answer.
What is the titration schedule and how long until I reach the full dose?
Understanding the dose escalation timeline sets expectations for when you will see maximum effect. Semaglutide takes about 16-20 weeks to reach the target dose; tirzepatide takes 16-20 weeks for most patients. Your provider may adjust based on tolerability.
How long will I need to stay on this medication?
This is critical. GLP-1 therapy for obesity is typically long-term or indefinite, similar to blood pressure or cholesterol medication. Studies show significant weight regain when medication is stopped. Your provider should discuss the maintenance plan from the start.
About Side Effects and Safety
What side effects should I expect and how do we manage them?
Ask for specific guidance: anti-nausea strategies, hydration protocols, dietary adjustments during titration. A good provider proactively prepares you for common GI side effects rather than waiting for you to report them.
What are the warning signs that I should contact you immediately?
Know the red flags: severe persistent abdominal pain (pancreatitis risk), persistent vomiting over 24 hours, vision changes, signs of allergic reaction, neck lump or swelling. Understanding emergency vs. routine side effects reduces anxiety and ensures appropriate response.
Are there any contraindications with my current medications or health conditions?
Disclose everything: prescription medications, supplements, over-the-counter drugs, and health conditions including thyroid disease history, pancreatitis, gastroparesis, eating disorders, and pregnancy plans. Learn about how GLP-1 medications interact with your body.
About Monitoring and Follow-Up
What lab tests will you order and how often?
Baseline labs should include metabolic panel, A1C, lipids, and thyroid function at minimum. Ask about the ongoing monitoring schedule. Providers who skip monitoring are cutting corners on your safety.
How will we communicate between visits?
Understand the communication pathway: patient portal messaging, phone, email, or text. Know the expected response time. During titration, you may need guidance on side effects or dose timing that cannot wait for the next scheduled visit.
What does success look like and how will we measure it?
Discuss realistic weight loss expectations (10-20% body weight over 12-18 months), metabolic improvement goals, and how you will track progress. Setting concrete benchmarks keeps both you and your provider accountable.
About Cost and Access
What will my total monthly cost be?
Get a complete picture: medication cost, consultation/subscription fees, lab work fees, and any additional charges. Ask about manufacturer savings cards, patient assistance programs, and what happens if insurance coverage changes.
What if my insurance denies coverage?
Ask whether the provider assists with prior authorizations and insurance appeals. Many denials can be overturned. Also ask about alternative pricing (compounded options, different medications, cash-pay discounts) as backup plans.
Medical Disclaimer: This article provides suggested questions for your healthcare consultation and is not a substitute for professional medical advice. Your provider will tailor their recommendations to your individual clinical situation.
Frequently Asked Questions
What is the most important question to ask before starting GLP-1?
Ask about the long-term plan: 'What happens when I reach my weight goal — do I stay on this medication indefinitely?' Understanding that GLP-1 therapy is typically long-term helps set realistic expectations. Weight regain after stopping is common, so knowing the maintenance strategy upfront is essential for informed decision-making.
Should I ask about semaglutide vs tirzepatide?
Absolutely. Ask your provider why they recommend one over the other for your specific situation. Factors include your A1C level, insurance coverage, side effect sensitivity, and weight loss goals. Tirzepatide may produce more weight loss and better A1C reduction, while semaglutide has more long-term cardiovascular outcomes data. Your provider should explain their reasoning.
What should I ask about side effects?
Ask: 'What side effects are most common, how do you manage them, and at what point would we consider stopping or switching?' Also ask about warning signs that require immediate attention (severe abdominal pain, persistent vomiting, vision changes). Understanding the difference between expected manageable side effects and concerning ones helps you respond appropriately.
Should I ask about drug interactions?
Yes. Tell your provider about every medication, supplement, and over-the-counter product you take. GLP-1 medications can affect absorption of oral medications due to slowed gastric emptying. Birth control pills, thyroid medication, and diabetes drugs may need timing or dose adjustments.
What cost-related questions should I ask?
Ask: 'What will my total monthly cost be, including medication, visits, and labs? Do you accept my insurance? Are there manufacturer savings programs? Is a compounded version available and appropriate? What happens to my cost if I lose insurance or change plans?' Understanding the financial commitment upfront prevents surprises.
Ask Us Anything About GLP-1
Our providers welcome your questions and take the time to answer every one.
Get Started TodaySources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).